StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Interview with Tripp posted today

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Apr 14, 2021 9:00pm

128 Views

Post# 32998172

RE:RE:RE:RE:Interview with Tripp posted today

You guys have been unfairly hard on Cactus, he has raised some valid points. Some are too sensitive to ANY criticism but there is no doubt that this rollout was botched and the share price reflects that. My question is who MIGHT have benefitted from the runup on the Thursday and the subsequent 50% loss in value. Nobody is questioning Aristotle, at least I'm not, but how and maybe more importantly why was this handled so poorly?